GSK

The US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.   Jesduvroq is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the US.  Tony Wood, President and Chief […]

Thousands of US lawsuits claiming that the heartburn drug Zantac caused cancer have been dismissed on the basis that they are not backed by sound science.  The ruling against around 50,000 claims was made by US District Judge Robin Rosenberg in West Palm Beach, Florida. The manufacturers have repeatedly asserted that Zantac does not cause […]

A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.  The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in the future which could help address the TB […]

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at CER.   The quarterly results are […]

New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over. In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination. The interim analysis data from […]

GSK’s annual Palio meeting is taking place with a focus on how preventative approaches to disease can help mitigate climate change.  GSK’s ‘Vaccines for a sustainable planet’ meeting is gathering 65 experts across immunology, vaccinology, epidemiology, and policy throughout 7-8 July.  The meeting will include a range of plenary sessions and working group discussions that […]

GSK has completed its acquisition of the biopharmaceutical company Sierra Oncology, boosting its portfolio of oncology medicines.  The deal was announced back in April this year and sees GSK acquiring Sierra Oncology for a total of $1.9 billion. The acquisition will give GSK access to Sierra’s late-stage candidate momelotinib, which is being developed to treat […]

Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.  A number of recently announced deals by pharma companies has brought some excitement back into the sector after a rather stagnant period of activity.   At the start of June, GSK announced it would be […]

GSK is to invest £1 billion over the course of 10 years into research on infectious diseases that largely affect low-income countries.   In particular, the pharmaceutical company will aim to develop new vaccines and medicines that prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR) – all […]

GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the company has announced.  The approval of GSK’s Priorix in the US gives patients another option for being vaccinated against MMR. The vaccine is already licensed in over 100 countries and more than 800 million doses have been […]